Title: Human Metapneumovirus seroprevalence and PCR trends - Findings from a Tertiary Care Hospital in India.

Corresponding Author

•Dr. Sadhana Yelamanchili, MD, FRCPATH(UK)

Director & HOD of Micro Biology

Department of Micro Biology

AIG HOSPITALS

Mind space road, Gachibowli, Hyderabad, Telangana, 500032 India

Contact No: 9885477933

e-mail: dr.sadhana@aighospitals.com

•Dr. Deepika Gujjarlapudi, MD, MBBS

Director & HOD Biochemistry

Department of biochemistry

AIG HOSPITALS,

Mind space road road, Gachibowli, Hyderabad, Telangana, 500032 India

Contact no: 8074010671

e-mail : drd.gujjarlapudi@aighospitals.com

•Dr. Nagamani Chella, MD, MBBS

Consultant Microbiologist

Department of Micro Biology

AIG HOSPITALS

Mind space road, Gachibowli, Hyderabad, Telangana, 500032 India

e-mail: dr.nagamanichella@aighospitals.com

•Dr. Sushma Yadav B, MD, MBBS

Consultant Microbiologist

Department of Micro Biology

AIG HOSPITALS

Mind space road, Gachibowli, Hyderabad, Telangana, 500032 India

e-mail: dr.sushmay@aighospitals.com

•Mr.Venkata Rajesh Dulla, Msc In Microbiology

Lab Manager

Department of Microbiology

AIG HOSPITALS

Mind space road, Gachibowli, Hyderabad, Telangana, 500032 India

e-mail: venkata.rajesh@aighospitals.com

•Dr Nageshwar reddy Duvvur, MD, DM,D.SC, FAMS, FRCP, FASGE, FACG, MWGO.

Chairman & Chief of Gastroenterology

AIG HOSPITALS

Mind space road, Gachibowli, Hyderabad, Telangana, 500032, India

Contact No:9701555800

e-mail: deepikapavanbio@gmail.com

ABSTRACT

Human Metapneumovirus (hMPV) is a paramyxovirus that was detected in India first in 2004. It causes a mild common cold in most cases but serious illness has developed in some young children, adults >65 years and the immunocompromised.

AIM: To study the age related prevalence of IgG antibodies in the population and also to determine the percent positivity and seasonal variation of hMPV infection.

MATERIAL AND METHODS: This cross-sectional study assessed seroprevalence by testing 820 serum samples collected between January 25th – 31st 2025 for hMPV IgG antibodies by ELISA and stratified according to age and sex. hMPV PCR trends: Retrospective data from the 1276 tests for Respiratory Viruses done at our centre during 2023 and 2024 were analysed and comprised of age groups 0-18, 19-30 ,31-45, 45-60 and > 60 years. The relationship between gender (M/F) and outcome (positive/negative) across various age groups was analysed using the chi-square test for independence in Graph Pad Prism 8.0.

RESULTS: **Seroprevalence study**: Overall hMPV IgG Antibody Positivity was 53.4%. Antibody positivity was higher in above 60 years when compared to other groups and was statistically significant (P=0.0001) and female predominance is seen.

In hMPV PCR trends: A higher percentage of positivity were observed in > 60years individuals who had hospitalisation when compared to the other groups which was statistically significant(P=0.0001). Overall Percent positivity was 7.8% in 2023 and 3.8% in 2024. Seasonal peaks occurred in Feb-Mar and Oct. 92.6% of patients were discharged and doing well on follow-up and only 7.4% deaths were seen.

CONCLUSION: Our finding highlight around 53.4% of the total study population had hMPV IgG antibodies. PCR positivity and antibody positivity was higher in individuals over 60 who had other comorbidities. Hospitalization and mortality rates are significantly high in these groups. Vaccine development for high-risk individuals is recommended.

INTRODUCTION:

Human Metapneumovirus (hMPV) is one of the viruses that cause the common cold. Most people are infected by 5 years of age. Most cases are mild, but young children, adults over 65 and people with weakened immune systems are at a higher risk of serious illness.

The virus is an enveloped virus and classified in the Paramyxovirus family (pneumoviridae subfamily). It was first identified in 2001 in Netherlands. It was detected in India in 2004. It is found around the world. Two major strains, designated A and B each with two subtypes have been identified, by antigenic and genetic analysis. [1] N. Devenathan et al [9] in their study reported the circulation of emerging lineages A2.2.1& A2.2.2 among children under 5 years of age in south India.

Despite its global prevalence, the Indian population's hMPV IgG seroprevalence data is sparse. Amid reports of increased hMPV cases in China, we investigated age-related hMPV IgG antibody prevalence, PCR trends and seasonal variations, aiming for respiratory outbreak preparedness and public health interventions.

MATERIALS AND METHODS:

Study design: This was a cross-sectional study conducted at AIG Hospitals, Hyderabad, India, a high volume multispecialty tertiary care centre, that was also a designated COVID-19 centre at the height of the pandemic. For seroprevalence study 820 serum samples from the department of Serology and Biochemistry collected between January 25th – 31st, 2025 were tested for hMPV IgG antibodies by ELISA method. For the hMPV PCR trends study, we analysed retrospective data from RT-PCR tests conducted at AIG Hospitals in 2023 and 2024. The study included 1276 samples tested for human metapneumovirus during this period. Patient demographics were obtained from the EMR- age, gender, comorbidities, co-infections and associated hospitalization data were also recorded. Samples were from different age groups (0-18, 19-30, 31-45,46-60 and >60 years) and both sexes representing a cross-section of the population.

ETHICAL STATEMENT

Written informed consent was obtained from all study participants prior to enrolment. All procedures were performed after acquiring necessary approvals from Institutional Ethics Committee approval was given (approval Number: AIG/IEC-Post BH&R66/01.2025-01).

Laboratory methods

RT PCR Assay: Samples were tested for respiratory viruses by one of the methods- Biofire Pneumonia Panel (Filmarray Multiplex PCR assay, Biomerieux) or Respiratory Combined Panel (Multiplex PCR by TRUPCR,3B BlackBio Biotech India Ltd.). For Biofire Pneumonia Panel respiratory samples (Sputum, BAL or ET samples) were sent at 2-8^0 C and testing was done within 4 hrs of sample reaching the Lab. For the respiratory combined panel, Nucleic acid extraction was done by TRUPCR Total Nucleic Acid Extraction kit. PCR was done as per Manufacturer's instructions. For PCR Test by the combined Respiratory Panel,

Nasopharyngeal swabs were collected in 3 ml of Viral Transport medium, transported and stored at 2-8^0 C. PCR was done within 24 hrs.

Elisa Test: For Elisa test, serum was separated and stored at 2-8^{0}C. Testing was performed within 48 hrs. HMPV-IgG Elisa kit (Cat. No: SLY3967Hu) manufactured by SUNLONG biotech Co. Ltd was used. This is an Indirect Elisa. The test was performed as per manufacturers' instructions. As discussed by Guilan Lu et al [5] the mean value and SD of the OD 450nm of the negative Control serum was calculated. Based on the formula: Cut-Off value = mean OD 450nm of the negative sera + 3SD. A tested sample was scored as positive if its OD 450nm value was above the cut-off value.

Statistical Analysis:

The relationship between gender (male/female) and outcome (positive/negative) across various age groups was analysed using the chi-square test for independence in Graph Pad Prism 8.0. Data were organized into contingency tables to compare observed frequencies of positive and negative outcomes for males and females. The chi-square test assessed whether gender and outcome were significantly associated by comparing observed counts to expected counts under the null hypothesis of independence. A p-value was calculated for each age group; if $p \leq 0.05$, the null hypothesis was rejected, indicating a significant association between gender and outcome. Graphical representations, such as bar graphs or contingency plots, were used to visualize results. The analysis helped identify significant differences or patterns in the distribution of outcomes between genders across age groups.

RESULTS:

A total of 820 serum samples were tested for hMPV IgG antibodies. This included 438 samples from males and 409 samples from females. Demographic details and antibody test results are tabulated in Table 1.

Table : 1 Demographic Details and HMPV IgG Antibody Positivity						
Age groups	Total Tested	Total Positive	Males Tested	Males Positive	Female Tested	Female Positive
0-18 yr	165	88 (53.3%)	82	42 (51.2%)	83	46 (55.4%)
19-30 yr	165	56 (33.9%)	82	19 (23.2%)	83	37 (44.6%)
31-45 yr	164	86 (52.4%)	83	54 (65.1%)	81	32 (39.5%)
46-60 yr	162	81 (50%)	81	39 (48.1%)	81	42 (51.9%)
>60 yr	164	127 (77.4%)	83	61 (73.5%)	81	66 (81.5%)
Total	820	438 (53.4%)	411	215 (52.3%)	409	223 (54.5%)

Overall percent positivity was 53.4%. For individuals above 60 years had higher antibody positivity and female predominance is seen and was statistically significant (P=0.001). In the 19-30 years age group the antibody percent positivity was more in females and was statistically significant (P=0.003). Similarly, in the age group 31-45 years percent positivity was more in males (P = 0.001)

Fig-1   SEX DISTRIBUTION OF HMPV IgG ANTIBODY

Fig-2   AGE DISTRIBUTION OF HMPV IgG ANTIBODY

All Samples tested in year 2023 and 2024 for respiratory viruses by PCR were analysed for hMPV positivity. Demographic details and outcome in terms of discharged/death were obtained from EMR. A total of 619 samples in year 2023 and 657 samples in year 2024 were tested. Percent Positivity for hMPV in 2023 was 7.8% (48/619) and in 2024 3.8%(25/657).

Demographic details and hMPV PCR test results for both years are given in Table 2 (2023) and Table 3 (2024)

Table:2 hMPV PCR Data - 2023

Age Groups	Total Tested	Total Positives	Males Tested	Males Positive	Females Tested	Females Positive
<18	9	0	5	0	4	0
19-30	32	4/32 (12.5%)	23	4/23 (17.4%)	9	0
31-45	70	4/70 (5.7%)	46	4/46 (8.7%)	24	0
46-60	148	7/148 (4.7%)	101	4/101 (4%)	47	3/47 (6.4%)
>60	360	33/360 (9.2%)	260	20/260 (7.7%)	100	13/100 (13%)
Total	619	48/619 (7.8%)	435	32/435 (7.4%)	184	16/184 (8.7%)

Table:3 hMPV PCR Data - 2024

Age Groups	Total Tested	Total Positives	Males Tested	Males Positive	Females Tested	Females Positive
<18	21	0	10	0	11	0
19-30	30	0	17	0	13	0
31-45	81	2/81 (2.5%)	39	2/39 (5.1%)	42	0
46-60	144	6/144 (4.2%)	86	2/86 (2.3%)	58	4/58 (6.9%)
>60	381	17/381 (4.5%	253	15/253 (5.9%)	128	2/128 (1.6%)
Total	657	25/657 (3.8%)	405	19/405 (4.7%)	252	6/252 (2.4%)

Fig-3　　　　　　　**SEX DISTRIBUTION OF RT PCR 2023**

Fig-4　　　　　　　**AGE DISTRIBUTION OF RT-PCR 2023**

Fig-5   **SEX DISTRIBUTION OF RT-PCR 2024**

Fig-6   **AGE DISTRIBUTION OF RT- PCR 2024**

Month wise hMPV PCR percent positivity for year 2023 is given in Table 4 and for year 2024 is given in Table 5 and depicted in Figures 7 & 8 respectively. Seasonal variation is seen with hMPV percent positivity with peaks occurring in February-march and October.

Table 4 : Month wise hMPV PCR percent Positivity-2023 (Total samples tested 619)

	Jan	Feb	Mar	Apr	May	June	Jul	Aug	Sep	Oct	Nov	Dec	Total
Total samples tested	68	81	60	34	22	25	30	51	81	84	44	39	619
No Positive for HMPV	2	7	7	0	0	0	1	5	9	13	2	2	48
HMPV Percentage (%)	2.94	8.64	11.6	0	0	0	3.33	9.8	11.11	15.47	4.54	5.12	7.8

Table 5 :Month wise hMPV PCR percent Positivity - 2024 (Total samples tested 657)

	Jan	Feb	Mar	Apr	May	June	Jul	Aug	Sep	Oct	Nov	Dec	Total
Total samples tested	49	77	85	61	35	29	45	79	84	46	35	32	657
No positive for HMPV	1	3	2	1	0	0	0	5	5	6	1	1	25
HMPV Percentage (%)	2.04	3.89	2.35	1.63	0	0	0	6.32	5.95	13.04	2.85	3.12	3.8

Fig-7.

Fig-8.

Among the 1276 tested patients, 840 were Males and 436 were females. 73 patients (51 Males & 22 females) tested positive by hMPV PCR in the year 2023 and 2024 (combined). Patient demographics are given in Table 6. 6.7% (50/741) positivity is seen in age group > 60 years.

Table: 6 Age wise distribution of 73 Patients who tested Positive for hMPV by PCR in the years 2023 & 2024(Combined)

Age Groups	Number Positive for hMPV PCR	Percent Positivity
0-18 years	0	0
19-30 years	4	4/62 (6.5%)
31-45 years	6	6/151 (4.0%)
46-60 years	13	13/292 (4.5%)
>60 years	50	50/741 (6.7%)
Total Positive	73	73/1276 (5.72%)

Admission and Outcome status of positive patients is given in Table 7. 93.2% (68/73) were in patients of which 92.6% (63/68) got discharged and were doing well on follow up.

Table :7 Admission and Outcome status of 73 Patients who tested Positive for hMPV by PCR in the years 2023 & 2024(Combined)

Admission status	In-Patient	Out Patient
Total Number	68 /73 (93.2%)	5/73 (6.8%)
Deaths	5/68 (7.4%)	-
Discharges	63/68 (92.6%)	-

Fig-9 DISTRIBUTION WITH CO-INFECTIONS   **Fig-10 DISTRIBUTION WITH MORBIDITY AND MORTALITY**

DISCUSSION:

A Cross-sectional seroprevalence study conducted in the month of January 2025 from 25th to 31st showed that 53.4% of the study population had detectable IgG antibodies to hMPV indicating exposure to the Virus.

Our study indicates that among the 820 samples tested 53.3% (88/165) of subjects aged   0-18 years, 33.9% (19/30) aged 19-30 years, 52.4% (86/164) aged 31-45 years,50% (81/162) aged 46-60 years and 77.4% (127/164) aged >60 years were seropositive for hMPV. There was only a marginal difference in seropositivity in males (52.3%) and Females (54.5%). An Indian Study by Banerjee et al, [4] from Delhi in the Year 2011 reported an overall percent positivity of 79% (79/100) whereas our study shows 53.4% (438/820) Positivity. Guilan Lu et al [5] in 2011 reported 100% Positivity in subjects 20 years and above.

Prevalence of hMPV may differ between geographical locations. There are no seroepidemiological studies from Southern India. Our results vary from the one report published from India in 2011 [4.] Number of Paediatric patients attending our hospital is considerably lower than adults. Hence we did not have data for subjects below 1 year. There is a detectable low seroprevalence among the age group 19 -30 years. In the 19-30 years age group females had comparatively higher seroprevalence (44.6 %) than males (23.2%). Whereas in the 31-45 years age group it was opposite, higher percentage of males (65.1%) had antibodies than females (39.5%).

There is seasonal variation in hMPV percent positivity. From April to July the percent positivity of hMPV is very low in both years with no cases detected in May and June in both years (Table 4 and 5 and Figures 7 and 8)

From August the percent positivity increases gradually with a peak in October (late Monsoon) tapering off from November to January and gradually increasing again showing a second peak from February to March (Late winter). Mridu Anand et al, [3] reported a similar

bimodal peak in incidence of respiratory viruses from Hyderabad during their study period (2017 – 2019)

In year 2023 of the total 619 tests done 70.3% (435/619) were males and 29.7% (184/619) were females. However overall percent positivity was slightly higher in females 8.7% (16/184) compared to males 7.4% (32/435). Table 2   In the year 2024 the number of males who got tested showed a slight decrease 61.6% (405/657) and there was an increase in the number of females who got tested 38.4% (252/657). The percent positivity has come down significantly in both males 4.7% (19/405) and females 2.4% (6/252) Table 3.

In both years, hMPV was not detected in females up to the age of 45 years. However, antibodies were detected when tested in January 2025 which indicates asymptomatic infections and circulation of the virus.

Over the period of two years it is observed that the PCR positivity has come down by 50%, from 7.8% in 2023 to 3.8% in 2024. Nandhini Et al [2] in 2016 reported similar findings from Puducherry, India during their study period from 2011 – 2013. They reported a percent Positivity of 15% in 2011, 5% in 2012 and 3% in 2013.

In our study, analysis of hMPV PCR Positive patients showed that 93.2% of them were hospitalised, of which 7.4% (Table.7) expired. P. Loubet et al in a study from France reported a mortality of 4% in hospitalised patients whereas Sang-Ho Choi et al reported an in-house mortality of 38.0%.

Of the 73 hMPV PCR Positive patients 46 (63%) had other virus co-infections of which Influenza A (H3N2) was the highest (93.5%) (Supplemental Table S1). 27 patients (37%) were infected with only hMPV out of which 5 (18.5%) had expired. Edward E. Walsh et al reported dual viral infections in 22.9% in hospitalised patients and 7% deaths in hMPV alone infected patients.

Limitations and Strength

Ours is a single-centre study and hence generalizations cannot be made.

Our study looked at the presence of antibodies qualitatively and did not quantitate. We also did not look specifically for neutralizing antibodies, which confer protection against hMPV infection.

Our study did not look at the hMPV genotyping and hence do not know the circulating lineages and their association with disease severity, if any.

Our hospital does not have many patients in the 0-5 years age group and hence could not assess the burden of hMPV infections in this age group.

STRENGTHS

The study is however strengthened by a large sample size and immunological profiling of the study population that provides valuable insights for further extensive immunological studies for outbreak preparedness

CONCLUSION:

53.4% (438/820) of study population had detectable IgG antibodies to hMPV indicating exposure to the virus.

Percentage of population in whom antibodies are detected is lower compared to studies in 2011. This may be due to the lower levels of virus circulation in the population and also waning immunity.

hMPV PCR positivity and antibody positivity was more in the age group above 60 with comorbidities

hMPV circulates in the population throughout the year with peaks in February - March and October. This is similar to other respiratory viruses. Over the years, the percent positivity is coming down, which probably explain the lower seroprevalence of hMPV IgG antibodies.

Our study findings show that hMPV infections are a significant cause of hospitalization due to viral respiratory tract infections and cause considerable mortality. Development of an hMPV vaccine for use in high risk individuals would be beneficial and should be considered.

ACKNOWLEDGMENTS:

The authors acknowledged the patients who participated in the study. The authors are also grateful to the institution from where we collected our data and authors/editors/publishers of all those articles, journals, and books from where the literature for this article has been reviewed and discussed. This study was supported by all the technical staff of Biochemistry and Microbiology departments of AIG Hospitals.

Source of funding: NIL

Conflict of Interest: There is no conflict of interest among the authors.

Authors' Contribution:

Dr. Sadhana & Dr. Deepika and Designed the study and analysed the data. And also prepared the Manuscript and Performed the Statistical analysis.

Dr. Nagamani , Dr. Sushma Collected the clinical data.

Mr. Rajesh Performed the Tests

Dr. D Nageshwar Reddy gave Administrative support and made Critical analysis.

Dr. Deepika, Dr. Sadhana, helped in final editing and approved the Manuscript.

REFERENCES:

1. Biacchesi S, et al. Genetic diversity between human metapneumovirus subgroups. Virology 2003;315:1–9.

2. Prevalence of Human Metapneumovirus infection among patients with influenza-like illness report from a Tertiary Care Center, Southern India. G. Nandhini Et al, IJMM, 2016 Jan -Mar; 34(1) : 27-32

3. Seasonal incidence of respiratory viral infections in Telangana, India: Utility of a Multiplex PCR assay to bridge the knowledge gap, Mridu Anand, Pavani Nimmala, Tropical Medicine and Interventional Health, Vol 25 No 12 PP 1503 - 1509, December 2020.

4. Seroepidemiological study of human metapneumovirus in New Delhi, India. S. Banerjee et al, Indian Journal of Medical Microbiology, (2011)vol.29,No.4:363-7

5. Large -scale seroprevalence analysis of human metapneumovirus and human respiratory syncytial virus infections in Beijing, China. Guilan Lu et al,Virology Journal 2011, vol 8,No 62

6. Human Metapneumovirus Infections in Adults Another Piece of the Puzzle Edward E. Walsh, et al. *Arch Intern Med.* 2008;168(22):2489-2496.

7. Characteristics of human metapneumovirus infection in adults hospitalised for community-acquired influenza-like illness in France,2012-2018: a retrospective observational study. P. Loubet et al. Clinical Microbiology and Infection 27(2021)127e1-127.e6

8. Outcomes of severe human metapneumovirus-associated community acquired pneumonia in adults, Sang-Ho Choi et al.Journal of Clinical Virology 117(2019) 1-4

9. Emerging lineages A2.2.1 and A2.2.2 of human metapneumovirus (hMPV) in pediatric respiratory infections: Insights from India Nivedha Devanathan e tal IJID 2024 Nov 12;14:100486. doi: 10.1016/j.ijregi.2024.100486

HMPV PCR-2024

Mortality Vs Morbidity

Mortality
23%

Morbidity
77%

■ Morbidity ■ Mortality

HMPV IgG Antibody

HMPV PCR-2023